Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21984307 | 0.93 | ALDH1A1 (0.33) | PIM3LIMK1F9ABCB1 | |
| SCHEMBL17369878 | 0.91 | PIM3 (0.37) | PIM3LIMK1F9RXRARXRB | |
| SCHEMBL15614252 | 0.90 | ALDH1A1 (0.35) | PIM3LIMK1F9ABCB1RXRA | |
| SCHEMBL21984072 | 0.90 | ALDH1A1 (0.35) | LIMK1F9ABCB1RXRARXRB | |
| SCHEMBL18802649 | 0.89 | ALDH1A1 (0.34) | PIM3LIMK1F9ABCB1RXRA | |
| SCHEMBL15614352 | 0.89 | PIM3 (0.36) | PIM3LIMK1F9ABCB1RXRA | |
| SCHEMBL15614266 | 0.89 | PIM3 (0.37) | PIM3LIMK1F9ABCB1RXRA | |
| SCHEMBL17369901 | 0.89 | GPR3 (0.33) | PIM3F9RXRARXRB | |
| SCHEMBL26687127 | 0.89 | ALDH1A1 (0.37) | PIM3LIMK1F9ABCB1RXRA | |
| SCHEMBL26687118 | 0.89 | ALDH1A1 (0.37) | PIM3LIMK1F9ABCB1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009845-A1 | ORGANIC ELECTRIC ELEMENT COMPRISING A PLURALITY OF EMISSION-AUXILIARY LAYERS AND ELECTRONIC DEVICE COMPRISING IT | DUK SAN NEOLUX CO., LTD. (KR) | 2023-01-12 | — | — | US | disclosed |
| US-20210184129-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD (KR) | 2021-06-17 | — | — | US | disclosed |
| US-10573819-B2 | Compound for organic electronic element, organic electronic element comprising the same, and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2020-02-25 | — | — | US | disclosed |
| US-20170288148-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT COMPRISING THE SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2017-10-05 | — | — | US | disclosed |
| US-20170288148-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT COMPRISING THE SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10573819-B2 | Compound for organic electronic element, organic electronic element comprising the same, and electronic device thereof | OCIAD1, GPX1, PIEZO1 | PIM3 2607/4885LIMK1 99/4885F9 1342/4885 |
| US-20170288148-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT COMPRISING THE SAME, AND ELECTRONIC DEVICE THEREOF | OCIAD1, GPX1, PIEZO1 | PIM3 2607/4885LIMK1 99/4885F9 1342/4885 |
| US-20210184129-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME AND ELECTRONIC DEVICE THEREOF | OR51E2, SLC39A11, WEE1 | PIM3 2095/4885LIMK1 184/4885F9 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.